These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9170008)

  • 1. Role of vasopressin in essential hypertension: racial differences.
    Bakris G; Bursztyn M; Gavras I; Bresnahan M; Gavras H
    J Hypertens; 1997 May; 15(5):545-50. PubMed ID: 9170008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients.
    Thibonnier M; Kilani A; Rahman M; DiBlasi TP; Warner K; Smith MC; Leenhardt AF; Brouard R
    Hypertension; 1999 Dec; 34(6):1293-300. PubMed ID: 10601133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin and renin-angiotensin maintain arterial pressure during PEEP in nonexpanded, conscious dogs.
    Kaczmarczyk G; Vogel S; Krebs M; Bünger H; Scholz A
    Am J Physiol; 1996 Nov; 271(5 Pt 2):R1396-402. PubMed ID: 8945979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of AVP in malignant DOC-salt hypertension: studies using vascular and antidiuretic antagonists.
    Filep J; Frölich JC; Földes-Filep E
    Am J Physiol; 1987 Nov; 253(5 Pt 2):F952-8. PubMed ID: 3688242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central and peripheral vasopressin interact differently with sympathetic nervous system and renin-angiotensin system in renal hypertensive rabbits.
    Kumagai H; Suzuki H; Ichikawa M; Matsumura Y; Jimbo M; Ryuzaki M; Saruta T
    Circ Res; 1993 Jun; 72(6):1255-65. PubMed ID: 8495554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased pressor function of central vasopressinergic system in hypertensive renin transgenic rats.
    Szczepańska-Sadowska E; Paczwa P; Loń S; Ganten D
    J Hypertens; 1998 Oct; 16(10):1505-14. PubMed ID: 9814623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of arginine vasopressin and arterial blood pressure in a population-based sample.
    Zhang X; Hense HW; Riegger GA; Schunkert H
    J Hypertens; 1999 Mar; 17(3):319-24. PubMed ID: 10100068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertensive response to acute aortic coarctation in chronic vasopressin deficient states.
    Fregoneze JB; Salgado MC; Castro e Silva EJ; Salgado HC
    Clin Exp Hypertens; 1995 Aug; 17(6):977-88. PubMed ID: 7581264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between AVP and sympathetic system in subtotal nephrectomy-saline hypertension: role of alpha and V1 receptors.
    Ozaykan B; Doğan A
    J Auton Nerv Syst; 2000 Jan; 78(2-3):165-71. PubMed ID: 10789696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of antihypertensive treatment on vasopressin secretion and on its osmoregulation in moderate hypertension.
    Del Bo A; Suraci S; Giuditta M; Mistò M; Zanchetti A
    J Hypertens; 1997 Nov; 15(11):1277-83. PubMed ID: 9383177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex differences in the endocrine predictors of essential hypertension. Vasopressin versus renin.
    Cowley AW; Skelton MM; Velasquez MT
    Hypertension; 1985; 7(3 Pt 2):I151-60. PubMed ID: 3888837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of vasopressin and other pressor systems to DOC-salt hypertension in rats.
    Mento PF; Wang HH; Sawyer WH
    Proc Soc Exp Biol Med; 1984 Jan; 175(1):58-63. PubMed ID: 6694969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular effects of arginine vasopressin during fluid deprivation in the rat.
    Aisenbrey GA; Handelman WA; Arnold P; Manning M; Schrier RW
    J Clin Invest; 1981 Apr; 67(4):961-8. PubMed ID: 7204578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the vascular effect of vasopressin in patients with mild essential hypertension.
    Bussien JP; Waeber B; Nussberger J; Hofbauer KG; Brunner HR
    Arch Int Pharmacodyn Ther; 1986 Jul; 282(1):130-9. PubMed ID: 3767522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of high sodium renal hypertension during chronic blockade of the vascular effects of vasopressin.
    Hinojosa C; Haywood JR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):492-6. PubMed ID: 2874211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats.
    Maeda C; Schaan B; Oliveira E; Oliveira V; De Angelis K; Irigoyen M
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):574-80. PubMed ID: 17581211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
    Morooka H; Iwanaga Y; Tamaki Y; Takase T; Akahoshi Y; Nakano Y; Fujiki H; Miyazaki S
    Circ Heart Fail; 2012 Jul; 5(4):484-92. PubMed ID: 22628529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does vasopressin sustain blood pressure in conscious spontaneously hypertensive rats?
    Filep J; Fejes-Tóth G
    Hypertension; 1986 Jun; 8(6):514-9. PubMed ID: 2872162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of arginine vasopressin in regulation of systemic arterial pressure.
    Rossi NF; Schrier RW
    Annu Rev Med; 1986; 37():13-20. PubMed ID: 3518603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.